|
Re: Question for the board
|
4
|
Resverlogix Corp.
|
Feb 16, 2016 11:17AM
|
|
Re: Vaccinex
|
4
|
BIOASIS TECHNOLOGIES INC
|
Sep 03, 2018 10:59AM
|
|
Re: NYAS Epigenetics: Cancer and Beyond Symposium eBriefing
|
4
|
Resverlogix Corp.
|
Jul 07, 2016 08:34PM
|
|
Re: Happy Canada Day!
|
4
|
Resverlogix Corp.
|
Jun 27, 2019 01:12PM
|
|
Re: Thinking back on an older discussion and wishing we had an update - Few items
|
4
|
Resverlogix Corp.
|
Jul 25, 2020 05:52PM
|
|
Re: Name Confusion
|
4
|
Zenith Epigenetics
|
Jul 29, 2020 01:21PM
|
|
Re: Bioasis announces a joint research collaboration with a leading pharmaceutical company.
|
4
|
BIOASIS TECHNOLOGIES INC
|
Jan 07, 2019 09:07AM
|
|
Re: Sparks Therapeutics Gene Therapy Deal
|
4
|
Resverlogix Corp.
|
Feb 24, 2019 09:51AM
|
|
Re: Anacetrapib Officially Bites the Dust
|
4
|
Resverlogix Corp.
|
Oct 26, 2017 04:19PM
|
|
Zenith Abstract at AACR 2017 Meeting April 1-5
|
4
|
Zenith Epigenetics
|
Mar 07, 2017 03:41PM
|
|
Re: What if
|
4
|
Resverlogix Corp.
|
Mar 07, 2019 09:33AM
|
|
Resverlogix and Richmond Club
|
4
|
Resverlogix Corp.
|
Jun 22, 2015 04:56PM
|
|
PROTAC-mediated BET degradation as a therapeutic strategy in CRPC
|
4
|
Zenith Epigenetics
|
Jun 14, 2016 12:00PM
|
|
Re: NYAS Epigenetics: Cancer and Beyond Symposium eBriefing
|
4
|
Zenith Epigenetics
|
Jul 07, 2016 08:37PM
|
|
Re: Cognitive Function with different combinations
|
4
|
Resverlogix Corp.
|
Dec 04, 2019 02:12PM
|
|
Re: Clarification received...
|
4
|
Resverlogix Corp.
|
Jun 10, 2018 08:51AM
|
|
Re: MACE Event rate,....
|
4
|
Resverlogix Corp.
|
Feb 28, 2019 01:32PM
|
|
Re: New Share Price Contest
|
4
|
Resverlogix Corp.
|
Oct 11, 2019 02:43PM
|
|
New Zenith immuno-oncology trial with Keytruda
|
4
|
Zenith Epigenetics
|
Oct 25, 2019 09:29AM
|
|
Re: ... did some looking back
|
4
|
Resverlogix Corp.
|
Jul 10, 2017 04:33PM
|
